...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Cost-effectiveness of a potential vaccine candidate for Haemophilus influenzae serotype 'a'
【24h】

Cost-effectiveness of a potential vaccine candidate for Haemophilus influenzae serotype 'a'

机译：嗜血杆菌血液血液筛选血液筛选的成本效果

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The preceding decade has witnessed the emergence of severe community-acquired acute infections caused by Haemophilus influenzae serotype a (Hia), with alarming incidence rates in North America, particularly among indigenous populations. The remarkable success of Hib conjugate vaccine over the past 20 years signify the development of an Hia vaccine candidate as a prevention measure to reduce the incidence of invasive Hia disease. However, quantifications of the long-term epidemiologic and economic impacts of vaccination are needed to inform decision on investment in Hia vaccine development and immunization programs. We sought to evaluate the cost-effectiveness of an Hia vaccine with a similar routine infant immunization schedules currently in practice for Hib in Canada. We developed and parameterized an agent-based simulation model using age-specific incidence rates reported for Nunavut, a Canadian territory with predominantly aboriginal populations. Our results, based on statistical analyses of the incremental cost-effectiveness ratio, show that an Hia conjugate vaccine is highly cost-effective. Sustaining an immunization program with vaccine coverages of 77% for primary series and 93% for booster dose over a 10-year period reduces the incidence of invasive disease by 63.8% on average from 9.97 to 3.61 cases, per 100,000 population. The overall costs of disease management in year 10 are reduced by 53.4% from CDN $1.863 million (95% CI: $1.229-$2.519 M) to CDN $0.868 million (95% Cl: $0.627-$1.1 20 M). The findings suggest an important role for a conjugate vaccine in managing Hia disease as a growing public health threat. (C) 2018 Elsevier Ltd. All rights reserved.
机译：前十年目睹了嗜血杆菌血液血液血液血液血液血液血液血液血液血清型血液血液血液（HIA）的出现，北美的惊人发出率率，特别是土着人口。在过去20年中，Hib缀合物疫苗的显着成功表示Hia疫苗候选人作为预防措施，以降低侵袭性Hia病的发病率。然而，需要对疫苗接种的长期流行病学和经济影响的量化，以便为亨伯疫苗开发和免疫计划的投资提供信息。我们试图评估HIA疫苗的成本效益，目前在加拿大的HIB实践中具有类似的常规婴儿免疫计划。我们使用针对Nunavut的年龄特异性发病率开发并参数化了基于代理的仿真模型，该境内是一个主要是土着人口的加拿大领土。我们的结果，基于统计分析的增量成本效益比，表明Hia缀合物疫苗具有高度成本效益。在10年期间维持疫苗覆盖率77％的疫苗覆盖率为77％，增压剂量为93％，平均每10万人口平均降低63.8％的入侵疾病发病率为63.8％。 10年内疾病管理的总成本减少了53.4％，从CDN 18.63亿美元（95％：1.229 - $ 2.229- $ 2.519米）到CDN $ 0.868万（95％CL：$ 0.627- $ 1.1 20米）。该研究结果表明，在康复疫苗在管理HIA病中作为不断增长的公共卫生威胁的重要作用。 （c）2018年elestvier有限公司保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号